The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Bristol Myers Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing ...

This pick list highlights constituents of the Morningstar US Large Cap Index that we believe offer investors the best risk-adjusted return prospects. Stocks of large-cap companies where neither ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

I will continue by comparing the revenue growth rates of Merck and Bristol-Myers Squibb, how often these two giants beat Wall Street analysts' expectations, and also compare their price-to-sales ...

This was the stock's second consecutive day of losses.

Bristol Myers Squibb pays investors a very attractive dividend that yields 4.1%. The company reported a loss last year, but that was a result of non-recurring expenses. Free cash flow looked ...

Business Wire • 9 days ago Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...